BiGEN participated in Series C fundraising of Noile-Immune Biotech (NIB), a Japanese private biotech company located in Tokyo. 

https://www.noile-immune.com/dcms_media/other/20210322_Implementation_of_Series_C_Round_Fundraising_En.pdf 

Implementation of Series C Round Fundraising 

Noile-Immune Biotech, Inc. (hereafter "the Company") announces approximately JPY 2.38 billion of capital increase through a third-party allotment of shares to the existing shareholders, Binex Co, Ltd., BiGEN Co., Ltd, and new investors, The Dai-ichi Life Insurance Company Limited, Binex Holdings, Shibuya Corporation, Healthcare Innovation Investment Limited Partnership, and KD Bio Investment Fund 4. 

Since our foundation in 2015, the Company has developed our in-house pipelines and collaborative pipelines of gene-modified immune cell therapies, mainly CAR-T cells using our core technology, i.e. PRIME (proliferation-inducing and migration-enhancing) technology. The Company will promote the conduct of clinical trial of our lead pipeline NIB-101 through this fundraising. 

NIB-101 is PRIME CAR-T cells that target GM2, a type of glycolipid expressed on certain types of cancer. The Company is preparing for the initiation of clinical trials of NIB-101 in 2021. 

We will continue to promote and expand multiple projects including NIB-101 to deliver truly efficacious treatments for cancer patients as soon as possible.